BPC-157 / TB-500 Blend research peptide is supplied to qualified Canadian institutions as a characterized, co-lyophilized laboratory material for in vitro combination studies. The vial contains equal stated masses of BPC-157 and TB-500.

In vitro, the blend is used when a protocol requires concurrent exposure to the gastric-juice-derived pentadecapeptide BPC-157 and the actin-binding heptapeptide motif of thymosin β4 (TB-500). Component literatures describe VEGFR2-proximal endothelial assays for BPC-157 and G-actin sequestration assays for TB-500. Co-lyophilization avoids an extra transfer step; it does not establish a single combined mechanism. Combination results should be read against single-component controls.

The preparation is 10 mg BPC-157 + 10 mg TB-500 per vial. PubChem identity is not assigned to the mixture as a whole; use per-component records and the lot COA. Store lyophilized at −20 °C, protected from light, and handle under the receiving institution's chemical-hygiene plan.

Lots are sourced from a GMP-aligned peptide manufacturing partner. Each component is tested independently and reported at the stated HPLC purity (≥98% by HPLC per component, lot-specific) on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.